Can I read Second malignant neoplasms after treatment of non-Hodgkin’s lymphoma—a retrospective multinational study of 189 children and adolescents on EtoBox?

Second malignant neoplasms after treatment of non-Hodgkin’s lymphoma—a retrospective multinational study of 189 children and adolescents by Andishe Attarbaschi; On behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group; Elisa Carraro; Leila Ronceray; Mara Andrés; Shlomit Barzilai-Birenboim; Simon Bomken; Laurence Brugières; Birgit Burkhardt; Francesco Ceppi; Alan K. S. Chiang; Monika Csoka; Alina Fedorova; Janez Jazbec; Edita Kabickova; Jan Loeffen; Karin Mellgren; Natalia Miakova; Olga Moser; Tomoo Osumi; Apostolos Pourtsidis; Charlotte Rigaud; Anne Uyttebroeck; Wilhelm Woessmann; Marta Pillon is a Medicine article available to read on EtoBox.

What is Second malignant neoplasms after treatment of non-Hodgkin’s lymphoma—a retrospective multinational study of 189 children and adolescents about?

Data on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin's lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980-2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) "other" SMNs (n = 28; 15%). In 37 patients (20%) preexisting disorders were reported with 90% having any kind of cancer predisposition syndrome (CPS). For the 189 primary NHL patients, 5-year overall survival (OS) after diagnosis of an SMN was 56 ± 4%, being worst for patients with preexisting disorders at 28 ± 8%. Five-year OS rates were 38 ± 8%, 59 ± 7%, 79 ± 8%, 34 ± 12%, and 62 ± 11%, respectively, for patients with myeloid and lymphoid neoplasms, carcinomas, CNS tumors, and "other" SMNs (p < 0.0001). Patients with SMNs after childhood NHL having a reported CPS, mostly mismatch repair disorders, carried a very poor

Who reads Second malignant neoplasms after treatment of non-Hodgkin’s lymphoma—a retrospective multinational study of 189 children and adolescents?

Author

Andishe Attarbaschi; On behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group; Elisa Carraro; Leila Ronceray; Mara Andrés; Shlomit Barzilai-Birenboim; Simon Bomken; Laurence Brugières; Birgit Burkhardt; Francesco Ceppi; Alan K. S. Chiang; Monika Csoka; Alina Fedorova; Janez Jazbec; Edita Kabickova; Jan Loeffen; Karin Mellgren; Natalia Miakova; Olga Moser; Tomoo Osumi; Apostolos Pourtsidis; Charlotte Rigaud; Anne Uyttebroeck; Wilhelm Woessmann; Marta Pillon

Publisher

Nature Publishing Group; Springer Science and Business Media LLC (ISSN 0887-6924)

Published

2020

Language

EN

Field

Medicine (Health Sciences)